| abstract |
A compound selected from those of formula (I), wherein W1 represents O, S, or -NR3 in which R3 represents hydrogen, alkyl, OH or CN; W2 represents a group selected from hydrohen, CF3, NH2, monoalkylamino, dialkylamino, alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkylalkyl, heterocycle, these groups being optionally substituted, or W1 and W2 form together a group of formula -N=X4-W3- as defined in the description, X1, X2 and X3 represent N or C optionally substituted, n is 0 to 8, Z represents -CR12R13, wherein R12 and R13 are as defined in the description, A represents a ring system, the groups R2 represent hydrogen or various chemical groups as defined in the description, q is 0 to 7; R1 represents hydrogen, alkyl, alkenyl, alkynyl, or a ring system, and optionally, its optical isomers, N-oxide, and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix metalloprotease. |